Eupraxia Pharmaceuticals Receives Buy Recommendations

Biotech firm's stock gets consensus buy rating from analysts

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) have received a consensus recommendation of "Buy" from the six brokerages currently covering the company, according to MarketBeat Ratings. One analyst has rated the stock a sell, three have given it a buy rating, and two have issued a strong buy recommendation. The average 12-month price target among the analysts is $15.50.

Why it matters

Positive analyst sentiment and price targets can boost investor confidence in a company's prospects and drive increased demand for its stock. As a clinical-stage biotech firm, Eupraxia's future success will depend heavily on the performance of its drug pipeline, making analyst views an important signal for the company's outlook.

The details

The analysts' recommendations come as Eupraxia Pharmaceuticals is advancing its lead therapeutic candidate through Phase 1 clinical trials for the treatment of systemic lupus erythematosus. The company's core strategy focuses on selectively expanding regulatory T cells, which play a key role in regulating the immune system and limiting inflammation.

  • Eupraxia Pharmaceuticals stock opened at $7.94 on Friday, March 6, 2026.
  • The company's stock has a 52-week range of $2.68 to $9.32.

The players

Eupraxia Pharmaceuticals Inc.

A clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases.

Wall Street Zen

An investment research firm that downgraded Eupraxia Pharmaceuticals from a "hold" rating to a "sell" rating.

Weiss Ratings

A financial research firm that maintained a "sell (d-)" rating on Eupraxia Pharmaceuticals.

Lifesci Capital

An investment bank that upgraded Eupraxia Pharmaceuticals to a "strong-buy" rating.

HC Wainwright

An investment firm that reiterated a "buy" rating and $12.00 price target on Eupraxia Pharmaceuticals.

Cantor Fitzgerald

An investment bank that increased its price target on Eupraxia Pharmaceuticals from $11.00 to $19.00 and maintained an "overweight" rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The consensus buy rating and price targets from analysts suggest growing confidence in Eupraxia Pharmaceuticals' drug pipeline and future prospects as a clinical-stage biotech firm. However, the mixed ratings from some research firms highlight the inherent risks and uncertainties involved in the company's development efforts.